Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYCAMORE trial of adalimumab plus methotrexate for juvenile idiopathic arthritis-associated uveitis
2010-021141-41Phase 2Completed
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Mar 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in juvenile idiopathic arthritis-associated uveitis (JIA-U), uveitis and juvenile idiopathic arthritis (JIA) comparing Adalimumab plus methotrexate with Methotrexate alone (2 arms). Primary endpoints: Treatment failure by anterior chamber inflammation, Treatment failure by concomitant medication use and 1 more. Started Mar 2011; status: completed.
02
Drugs
adalimumabmethotrexate
03
Conditions
juvenile idiopathic arthritis-associated uveitis (JIA-U)uveitisjuvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2010-021141-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021141-41.